Paolo Caimi, MD, Cleveland Clinic, Cleveland, OH, shares insights into the use of CD19-directed therapies in large B-cell lymphoma (LBCL), commenting on a study that evaluated the feasibility of sequencing CD19-targeted agents. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.